期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

P2Y_(12)基因多态性与PCI术后患者氯吡格雷反应变异性的关联分析 被引量：10

Evaluating association of P2Y_(12) gene polymorphisms with clopidogrel response variability in Chinese patients undergoing PCI
下载PDF
导出
摘要 目的:探讨P2Y12受体G52T基因多态性与经皮冠状动脉介入术(PCI)术后患者氯吡格雷反应变异性的关系。方法:提取109例PCI术后患者外周血基因组DNA,采用DNA测序技术检测P2Y12受体G52T基因多态性。以5、20μmol.L-1二磷酸腺苷为诱导剂,测定患者服用氯吡格雷前及服药后12、36 h血小板聚集率。结果:109例PCI术后患者中GG、GT和TT基因型分别占79.82%、17.43%和2.75%。两组患者(GG纯合子组和T基因携带组)在服用氯吡格雷前后不同时间点的最大血小板聚集率差异无统计学意义。结论:P2Y受体G52T基因多态性可能与PCI术后患者氯吡格雷反应变异性没有关联。 Objective： To explore the association of P2Y12 gene polymorphisms with clopidogrel response variability in Chinese patients undergoing percutaneous coronary intervention（PCI）.Methods： Genomic DNA was extracted from the leukocyte cells of each blood samples in 109 patients undergoing PCI.DNA sequencing analysis were employed to assess the polymorphism of P2Y12 gene G52T.Platelet aggregation（5 and 20 μmol·L-1 ADP） were measured at baseline,12 hours,36 hours after the clopidogrel loading dose.Results： The GG genotype,GT genotype,TT genotype were 79.82%,17.43% and 2.75%,respectively.There were no significant differences in platelet aggregation at different time points between two different P2Y12 genotypes（GG homozygote and T aelle carrier）.Conclusion： The P2Y12 G52T polymorphisms may not associate with the clopidogrel response variability in Chinese patients undergoing PCI.
作者 柳亚敏 刘乃丰
机构地区 中国药科大学药学院 东南大学附属中大医院心内科
出处 《东南大学学报（医学版）》 CAS 2011年第3期449-453,共5页 Journal of Southeast University(Medical Science Edition)
基金 中国药科大学巴斯夫研究生创新基金资助项目
关键词 P2Y12受体 G52T 经皮冠状动脉介入术 氯吡格雷反应变异性 P2Y12 receptor G52T percutaneous coronary intervention clopidogrel response variability
分类号 R815 [医药卫生—放射医学] Q786 [生物学—分子生物学]
  • 相关文献

参考文献12

  • 1ANGIOLILLO D J,FERNANDEZ-ORTIZ A,BERNARDO E,et al.Variability in individual responsiveness to clopidogrel:clinical implications,management,and future perspectives[J].J Am Coll Cardiol,2007,49(14):1505-1516.
  • 2MULLER I,BESTA F,SCHULZ C,et al.Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement[J].Thromb Haemost,2003,89(5):783-787.
  • 3GURBEL P A,BLIDEN K P,HIATT B L,et al.Clopidogrel for coronary stenting:response variability,drug resistance,and the effect of pretreatment platelet reactivity[J].Circulation,2003,107(23):2908-2913.
  • 4ANGIOLILLO D J,FERNANDEZ-ORTIZ A,BERNARDO E,et al.High clopidogrel loading dose during coronary stenting:effects on drug response and interindividual variability[J].Eur Heart J,2004,25(21):1903-1910.
  • 5ANGIOLILLO D J,FERNANDEZ-ORTIZ A,BERNARDO E,et al.PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation[J].Blood Coagul Fibrinolysis,2004,15(1):89-93.
  • 6FONTANA P,DUPONT A,GANDRILLE S,et al.Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects[J].Circulation,2003,108(8):989-995.
  • 7陈碧莲,李清,解勤之,谢伟,马琦琳.P2Y_(12)受体基因多态性在中国人群中的分布和对氯吡格雷疗效的影响[J].中国新药杂志,2008,17(16):1435-1439. 被引量：10
  • 8NGUYEN T A,DIODATI J G,PHARAND C.Resistance to clopidogrel:a review of the evidence[J].J Am Coll Cardiol,2005,45(8):1157-1164.
  • 9von BECKERATH N,von BECKERATH O,KOCH W,et al.P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose[J].Blood Coagul Fibrinolysis,2005,16(3):199-204.
  • 10FONTANA P,HULOT J S,de MOERLOOSE P,et al.Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects[J].J Thromb Haemost,2007,5(10):2153-2155.

二级参考文献13

  • 1FONTANA P, DUPONT A, GANDRILLE S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects [ J ]. Circulation,2003, 108(8):989 -995.
  • 2MEHTA SR, YUSUF S, PETERS RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J]. Lancet, 2000, 358(9281):527 -533.
  • 3YUSUF S, ZHAO F, MEHTA SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation[ J ]. N Engl J Med , 2001, 345 (7) :494 -502
  • 4NGUYEN TA, DIODATI JG, PHARAND C. Resistance to clopidogrel : a review of the evidence[ J]. J Am Coll Cardiol, 2005, 45(8) :1157 -1164.
  • 5VON BECKERATH N, VON BECKERATH O, KOCH W, et al. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose [ J ]. Blood Coagul Fibrinolysis, 2005, 16 ( 3 ) : 199 - 204.
  • 6ANGIOLILLO DJ, FERNANDEZ-ORTIZ A, BERNARDO E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease[J]. Thromb Res, 2005, 116(6) :491 -497.
  • 7BLIN N, STAFFORD DW. A general method for isolation of high molecular weight DNA from eukaryotes [ J ]. Nucleic Acids Res, 1976, 3(9) :2303 -2308.
  • 8LAU WC, GURBEL PA, WATKINS PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance [ J ]. Circulation, 2004, 109 ( 2 ) :166 -171.
  • 9TAUBERT D, VON BECKERATH N, GRIMBERG G, et al. Impact of P-glycoprotein on clopidogrel absorption [ J ]. Clin Pharmacol Ther, 2006, 80(5 ):486-501.
  • 10TAUBERT D, KASTRATI A, HARLFINGER S, et al. Pharmacokinetics of clopidogrel after administration of high loading dose [J]. Thromb Haemost, 2004, 92(2) :311 -316.

共引文献9

同被引文献113

  • 1苏冠华,王朝晖.血小板膜GPⅡb/Ⅲa基因多态性与冠心病[J].心血管病学进展,2006,27(z1):14-16. 被引量：3
  • 2张丽华,杜雪,何培源,蒋立新.P2Y_(12)受体拮抗剂最新研究进展[J].中华临床医师杂志（电子版）,2012,6(19):6001-6003. 被引量：3
  • 3蒙绪卿,廖小平,龙志刚.PAC-1和CD62P在脑梗死急性期的表达[J].国外医学（脑血管疾病分册）,2005,13(11):860-863. 被引量：6
  • 4ROSS R.Atherosclerosis-an inflammatory disease[ J]. N Engl J Med, 1999,340 (2) : 115-126.
  • 5LIBBY P. Inflammation in atherosclerosis [ J ]. Nature, 2002, 420 ( 6917 ) : 868- 874.
  • 6HANSSON G K.Inflammation,atheroselerosis, and coronary ar- tery disease[ J]. N Engl J Med,2005,352(16) :1685-1695.
  • 7JOHANSEN J S, JENSEN B V, ROSLIND A, et al. Serum YKL-40,a new prognostic biomarker in cancer patients? [ J]. Cancer Epidemiol Biomarkers Prev, 2006,15 ( 2 ) : 194-202.
  • 8HAKALA B E, WHITE C, RECKLIES A D. Human cartilage gp-39,a major secretory product of articular ehondrocytes and synovial cells, is a mammalian member of a chitinase proteinfamily[ J]. J Biol Chem,1993,268(34) :25803-25810.
  • 9BOOT R G, van ACHTERBERG T A,VAN AKEN B E,et al. Strong induction of members of the chitinase family of proteins in atheroselerosis: chitotriosidase and human cartilage gp-39 expressed in lesion maerophages [ J ]. Arterioscler Thromb Vase Biol, 1999,19 (3) :687-694.
  • 10SHACKELTON L M, MANN D M, MILLIS A J. Identification of a 38- kDa heparin- binding glycoprotein ( gp38k ) in differ- entiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling[ J ]. J Biol Chem, 1995,270 (22) : 13076-13083.

引证文献10

二级引证文献36

东南大学学报（医学版）
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部